Skip to main content
OpenTrials

Clinical trial condition

Hematologic Neoplasms

Explore clinical trials studying Hematologic Neoplasms. Study availability and eligibility vary by location and protocol.

1,027 public trials 268 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Neoplasms trial results

Recruiting

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

NCT06465433

Conditions
Hematologic Diseases, Hematologic Malignancies, Hematologic Neoplasms, +3 more
Locations
  • Petz Aladar County Teaching Hospital Győr, Hungary
  • Hospital S.M. Terni University of Perugia Terni, Italy
  • Samsung Medical Center Seoul, South Korea
  • Clinica Universitad de Navarra Pamplona, Spain
View Trial Details
Recruiting

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

NCT05786716

Conditions
Adnexal Diseases, Biliary Tract Diseases, Biliary Tract Neoplasms, +61 more
Locations
  • Belfast City Hospital Belfast, United Kingdom
  • University Hospital Birmingham Birmingham, United Kingdom
  • Birmingham Children's Hospital Birmingham, United Kingdom
  • Bristol Royal Hospital for Children Bristol, United Kingdom
View all 27 locations
View Trial Details
Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

NCT05768178

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +74 more
Locations
  • Belfast City Hospital Belfast, United Kingdom
  • University Hospital Birmingham Birmingham, United Kingdom
  • Bristol Haematology and Oncology Centre Bristol, United Kingdom
  • Addenbrooke's Hospital Cambridge, United Kingdom
View all 16 locations
View Trial Details
Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

NCT05770544

Conditions
Brain Diseases, Brain Neoplasms, Cancer, +30 more
Locations
  • Belfast City Hospital Belfast, United Kingdom
  • University Hospital Birmingham Birmingham, United Kingdom
  • Birmingham Children's Hospital Birmingham, United Kingdom
  • Bristol Royal Hospital for Children Bristol, United Kingdom
View all 27 locations
View Trial Details
Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

NCT05770037

Conditions
Adenocarcinoma, Anaplastic Large Cell Lymphoma, Cancer, +37 more
Locations
  • Belfast City Hospital Belfast, United Kingdom
  • University Hospital Birmingham Birmingham, United Kingdom
  • Birmingham Children's Hospital Birmingham, United Kingdom
  • Bristol Royal Hospital for Children Bristol, United Kingdom
View all 27 locations
View Trial Details
Recruiting

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

NCT06988475

Conditions
Cancer, Digestive System Diseases, Digestive System Neoplasms, +27 more
Locations
  • Belfast City Hospital Belfast, United Kingdom
  • University Hospital Birmingham Birmingham, United Kingdom
  • Bristol Haematology and Oncology Centre Bristol, United Kingdom
  • Addenbrooke's Hospital Cambridge, United Kingdom
View all 17 locations
View Trial Details
Recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

NCT06378138

Conditions
Hematologic Diseases, Hematologic Malignancies, Hematologic Neoplasms, +3 more
Locations
  • The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, China
  • Anhui Provincial Hospital (The First Affiliated Hospital of University of Science and Technology of China) Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
View all 53 locations
View Trial Details
Recruiting

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

NCT04707300

Conditions
Hematologic Diseases, Hematologic Malignancy, Hematologic Neoplasms, +11 more
Locations
  • Hôpital Saint Louis Paris, France
  • Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux Pessac, France
  • IUCT Oncopole Toulouse Toulouse, France
  • Institut Gustave Roussy Villejuif, France
View Trial Details

Related conditions